BJH - volume 8, issue Abstract Book BHS, february 2017
A. Camboni MD, PhD, C. Dachelet , E. Van den Neste MD, PhD, L. Sacre , L. Marot
BJH - volume 8, issue Abstract Book BHS, february 2017
G. Verstraete , S. Lefevre , S. Bailly MD, G. Di Prinzio , J. Devreux , J-P. Defour PhD, P. D’Abadie , P. Van Eeckhout , F. Kino , C. Goemare , N. Lepage , L. Michaux MD, PhD, V. Havelange MD, PhD, E. Van den Neste MD, PhD, C. Lambert MD, L. Knoops MD, PhD, M-C. Vekemans MD, X. Poiré MD
BJH - volume 7, issue 2, april 2016
V. De Wilde MD, PhD, D. Dierickx MD, PhD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD, C. Bonnet MD, PhD, M. André MD, A. Janssens MD, PhD, V. Van Hende MD, A. Van Hoof MD, PhD
Primary central nervous system lymphoma is a rare form of extranodal B cell lymphoma of the brain, the eyes, the meninges or the spinal cord in the absence of systemic lymphoma. The management of primary central nervous system lymphoma remains controversial, which is related to the rarity of the cases and the small number of controlled studies available. The present consensus report provides the guidelines proposed by the Belgian Hematology Society Lymphoproliferative Working Party for treating immunocompetent adult patients with primary central nervous system lymphoma.
(BELG J HEMATOL 2016;7(2):69–78)
Read moreBJH - volume 7, issue Abstract Book BHS, january 2016
A. Camboni MD, PhD, C. Dachelet , E. Van den Neste MD, PhD, L. Sacre , L. Marot
BJH - volume 7, issue Abstract Book BHS, january 2016
S. Amat , T. Tamakloe , N. Meité , V. Havelange MD, PhD, M-C. Vekemans MD, C. Lambert MD, E. Van den Neste MD, PhD, X. Poiré MD
BJH - volume 7, issue Abstract Book BHS, january 2016
T. Tamakloe , N. Meité , S. Amat , P. Janssens , L. Marot , J-P. Defour PhD, P. Saussoy MD, PhD, H. Poirel , L. Michaux MD, PhD, E. Van den Neste MD, PhD, L. Knoops MD, PhD, V. Havelange MD, PhD, C. Lambert MD, X. Poiré MD, M-C. Vekemans MD
BJH - volume 6, issue 5, december 2015
A. Janssens MD, PhD, E. Van den Neste MD, PhD, F. Offner MD, PhD, D. Bron MD, PhD
The Belgian Hematological Society Lymphoproliferative Working Party updated the 2012 recommendations on the best strategies for front-line and subsequent-line treatment of small lymphocytic leukaemia/chronic lymphocytic leukaemia. No treatment is necessary for patients without active and/or advanced disease, regardless of prognostic factors. When front-line treatment is indicated we recommend adding an anti-CD20 monoclonal antibody to chemotherapy except in frail patients: fludarabine, cyclophosphamide, rituximab for fit patients; bendamustine, rituximab for fit patients >65 years or unfit for fludarabine, cyclophosphamide, rituximab; and chlorambucil with obinutuzumab or rituximab for older patients with a geriatric profile, major comorbidities or a reduced performance status. The choice of treatment for patients with recurrent disease depends on the duration of response to the previous treatment, the type of treatment refractoriness and the presence of a 17p deletion/p53 mutation. As an alternative, chemoimmunotherapy can be proposed for patients with a late relapse. The novel B-cell receptor inhibitors are the best choice for those relapsing early, who have refractory disease or are unfit for chemoimmunotherapy. The B-cell receptor inhibitors are also first choice for each patient with a de novo or acquired 17p deletion/p53 mutation. Reduced intensity conditioning allogeneic stem cell transplantation should still be considered for patients with high-risk disease after response induction by the B-cell receptor inhibitors. We still have to encourage patients to enter clinical trials exploring new drug combinations.
(BELG J HEMATOL 2015;6(5): 195–202)
Read more
Top
